Research To Practice | Oncology Videos

Latest Episodes:

Lung Cancer | Breakfast with the Investigators: Current and Emerging Role of Antibody-Drug Conjugates in the Treatment of Lung Cancer Jul 08, 2024

Show notes

Featuring perspectives from Dr Rebecca S Heist, Dr Luis Paz-Ares and Dr Jacob Sands, moderated by Dr Sands, including the following topics:

Introduction (0:00)
Integration of Antibody-Drug Conjugates (ADCs) into the Care of Patients with Non-Small Cell Lung Cancer (NSCLC) and HER2 Alterations — Dr Paz-Ares (1:28)
Emerging Role of TROP2-Targeted ADCs for NSCLC — Dr Sands (23:12)
Other Promising Targets for ADCs for Lung Cancer — Dr Heist (39:07)

CME information and select publications

Myelofibrosis | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis Jul 02, 2024

Show notes

Featuring perspectives from Dr Aaron T Gerds, including the following topics:

Introduction: Myelofibrosis (MF) for Oncology "Newbies" (0:00)
Biology of MF (5:20)
Management of Anemia in MF (20:12)
Novel Strategies for MF (29:28)
Journal Club (46:12)

CME information and select publications

Prostate Cancer | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Prostate Cancer Jul 01, 2024

Show notes

Featuring perspectives from Dr Neeraj Agarwal, Dr Emmanuel S Antonarakis, Dr Andrew J Armstrong, Dr Tanya B Dorff and Dr Matthew R Smith, moderated by Dr Armstrong, including the following topics:

Introduction (0:00)
Optimizing the Management of Nonmetastatic Prostate Cancer — Dr Dorff (3:34)
Evidence-Based Selection of Treatment for Metastatic Hormone-Sensitive Prostate Cancer — Dr Smith (26:32)
New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (53:27)
Role of Novel Radiopharmaceuticals for mCRPC — Dr Armstrong (1:15:36)
Promising Investigational Approaches for Patients with Prostate Cancer — Dr Antonarakis (1:36:43)

CME information and select publications

Metastatic Breast Cancer | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Metastatic Breast Cancer Jun 28, 2024

Show notes

Featuring perspectives from Dr Aditya Bardia, Dr Harold J Burstein, Prof Giuseppe Curigliano, Dr Sara A Hurvitz, Dr Hope S Rugo and Dr Joyce O'Shaughnessy, moderated by Dr Rugo, including the following topics:

Introduction (0:00)
Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Hurvitz (4:38)
Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Burstein (30:11)
Selection and Sequencing of Treatment for Patients with HR-Positive, HER2-Negative mBC Who Experience Disease Progression on CDK4/6 Inhibition — Dr Rugo (48:15)
Current and Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Prof Curigliano (1:07:24)
Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:22:11)
Current and Future Strategies for the Care of Individuals with Endocrine-Refractory HR-Positive mBC — Dr Bardia (1:42:24)

CME information and select publications

Ovarian and Endometrial Cancer | Meet The Professors Live: Clinical Investigators Provide Perspectives on Actual Cases of Patients with Ovarian and Endometrial Cancer Jun 27, 2024

Show notes

Featuring perspectives from Dr Floor J Backes, Dr Mansoor Raza Mirza, Dr Ritu Salani, Dr Angeles Alvarez Secord and Dr Brian M Slomovitz, with cases presented by Dr Eric H Lee, Dr Priya Rudolph and Dr Lyndsay J Willmott, moderated by Dr Secord, including the following topics:

Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Salani

Introduction (0:00)
Case: A woman in her mid 60s with dementia who has peritoneal carcinomatosis with OC — Eric H Lee, MD, PhD (3:00)
Case: A woman in her mid 40s with advanced OC undergoes immediate cytoreduction — Lyndsay J Willmott, MD (9:52)

Current Management of Relapsed/Refractory (R/R) OC; Promising Novel Agents and Strategies Under Investigation — Dr Backes

Case: A woman in her late 40s with a BRCA2 germline mutation and high-grade serous OC — Priya Rudolph, MD, PhD (26:44)
Case: A woman in her mid 50s with platinum-sensitive recurrent OC who had not received a prior PARP inhibitor — Dr Willmott (33:35)

First-Line Therapy for Advanced Endometrial Cancer (EC) — Dr Mirza

Case: A woman in her early 60s diagnosed with endometrioid cancer presents with abdominal pain 2 years later — Dr Rudolph (49:44)
Case: A woman in her early 70s with microsatellite instability-high, mismatch repair-deficient Stage IV carcinosarcoma — Dr Willmott (56:44)

Current Therapeutic Options for R/R EC; Novel Investigational Strategies — Dr Slomovitz

Case: A woman in her early 60s with a history of serous endometrial cancer (EC) presents with recurrent disease 2 years later — Dr Rudolph (1:12:44)
Case: A woman in her late 70s with EC develops a cough 2 years after initial treatment — Dr Lee (1:19:50)

Role of HER2-Targeted Therapy in the Management of Advanced OC, EC and Other Gynecologic Cancers — Dr Secord

Case: A woman in her late 60s with endometrioid adenocarcinoma is admitted with abdominal distention — Dr Rudolph (1:34:55)
Case: A woman in her mid 30s with mucinous adenocarcinoma of the ovary is later diagnosed with a liver metastasis — Dr Lee (1:41:02)

CME information and select publications

Antibody-Drug Conjugates | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Optimal Implementation of Antibody-Drug Conjugates Jun 26, 2024

Show notes

Featuring perspectives from Ms Jamie Carroll, Ms Kelly EH Goodwin, Dr Erika Hamilton and Dr Hope S Rugo, including the following topics:

Introduction (0:00)
Overview of Antibody-Drug Conjugates (ADCs); HER2-Targeted ADCs for Breast Cancer — T-DM1, Trastuzumab Deruxtecan (7:22)
The Incidence and Management of Interstitial Lung Disease with ADCs (34:05)
ADCs Targeting Other Signaling Pathways in Breast Cancer — Sacituzumab Govitecan, Datopotamab Deruxtecan, Patritumab Deruxtecan (49:02)
ADCs for Other Tumor Types and Toxicities Associated with ADCs (1:14:53)

NCPD information and select publications

Hepatobiliary Cancers | Lunch with the Investigators: Hepatobiliary Cancers Jun 25, 2024

Show notes

Featuring perspectives from Dr Robin K (Katie) Kelley, Dr Edward Kim and Prof Arndt Vogel, and moderated by Dr Kelley, including the following topics:

Introduction (0:00)
Recent Developments in the Management of Early- and Intermediate-Stage Hepatocellular Carcinoma (HCC) — Dr Kim (1:58)
First-Line Therapy for Advanced HCC and Biliary Tract Cancers (BTCs) — Prof Vogel (22:24)
Integration of Targeted Therapy into the Management of Advanced BTCs — Dr Kelley (42:19)

CME information and select publications

Non-Small Cell Lung Cancer | Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer with an EGFR Mutation Jun 21, 2024

Show notes

Featuring perspectives from Dr Jonathan W Goldman, Dr Corey J Langer, Dr Joel W Neal, Dr Zofia Piotrowska, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics:

Introduction (0:00)
Contemporary Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Langer (2:08)
Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation — Dr Goldman (22:37)
Biological Rationale for and Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation — Dr Yu (43:23)
Other Emerging Strategies for Relapsed Metastatic NSCLC with an EGFR Mutation — Dr Sabari (1:03:33)
Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation — Dr Piotrowska (1:20:15)
Management of Toxicities Associated with Available and Emerging Therapies for NSCLC with an EGFR Mutation — Dr Neal (1:38:44)

CME information and select publications

Hormone Receptor-Positive Breast Cancer | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Hormonal Therapy for Hormone Receptor-Positive Breast Cancer Jun 20, 2024

Show notes

Featuring perspectives from Dr Harold J Burstein, Ms Kelly Fischer, Dr Komal Jhaveri and Ms Melissa Rikal, including the following topics:

Introduction (0:00)
The Utility of Genomic Assays in Treatment Decision-Making for HR-Positive, HER2-Negative Localized Breast Cancer (10:21)
The Role of CDK4/6 Inhibitors in Therapy for HR-Positive Breast Cancer (37:18)
Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive Metastatic Breast Cancer (mBC) (1:04:27)
Alpelisib and Capivasertib in Treatment for HR-Positive mBC (1:28:40)

NCPD information and select publications

Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Clinical Update on the Current Management of Advanced Urothelial Bladder Cancer' Jun 18, 2024

Show notes

Featuring perspectives from Dr Petros Grivas, including the following topics:

Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00)
Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16)
Perspective on recurrence mechanisms of NMIBC (22:21)
Potential implications of circulating tumor DNA-based research in the management of bladder cancer (25:27)
Importance of collaborative care for patients with bladder cancer (42:02)
Frequency of HER2 expression and approach to HER2 testing for metastatic UBC (mUBC); activity of trastuzumab deruxtecan (T-DXd) in HER2-positive solid tumors (46:57)
Monitoring and management of T-DXd-associated side effects (1:00:47)
Efficacy and ongoing investigation of the HER2-targeted antibody-drug conjugate disitamab vedotin; other promising agents and strategies under investigation for mUBC (1:07:32)
Results from the Phase III PROOF 302 trial of infigratinib versus placebo for patients with high-risk resected UBC with an FGFR3 genomic alteration (1:11:22)
Potential association between intravesical bacillus Calmette-Guérin administration and lower risk of being diagnosed with Alzheimer's disease in patients with bladder cancer; feasibility of internet-based, patient-driven germline genetic testing (1:16:12)

CME information and select publications